Driving T-Cell Immunotherapy To Solid Tumors

Driving T-Cell Immunotherapy To Solid Tumors

Image of T-Cell.  T cell receptor (TCR) gene therapy can target the immune system to solid tumors in ways CAR-T cells can’t match, but the field is still looking for a clear success. Last September, GlaxoSmithKline took over one of Adaptimmune Therapeutics’...
PAC-1 Trial in Humans with Brain Cancer Extended

PAC-1 Trial in Humans with Brain Cancer Extended

Timothy Fan and Paul Hergenrother A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the...